Skip to main content

SFDA Monitors 291 Violations During 4,677 Inspection Tours in June

2022-07-26

Saudi Food and Drug Authority (SFDA) monitored 291 violations in facilities under its supervision, during 4,677 inspection tours in all regions of the Kingdom of Saudi Arabia in June this year.

SFDA stated that it carried out 2,445 inspection tours to food facilities, 280 to pesticides and feed facilities, and 1,535 to pharmaceutical facilities and medical devices, in addition to routine visits and smart inspections.

Other News

Circular on General compliance with transportation and storage requirements

Circular on General compliance with transportation and storage requirements
Publication Date
2022-07-25
Applying Date
2022-07-25

SFDA Warns Against Herbal Product “Montalin Jamu” Due to Containing Active Medicinal Ingredients

Warning Date
    2022-06-28
Manufacture Company

Warning Reason
Correction Actions
Advices to Consumer

SFDA Warns Against Herbal Product “Montalin Jamu” Due to Containing Active Medicinal Ingredients

2022-06-28

The Saudi Food and Drug Authority (SFDA) has warned against the herbal product "MOUNTALIN JAMU PEGAL LINU DAN ASAM URAT" because it contains the active pharmaceutical ingredient "Paracetamol", produced by AIR MADU MAGELANG - INDONESIA POM TR.

  • To report sector-related issues

  • Call Centre 19999


Other Warnings

SFDA Inspects Hajj Medical Imports to Ensure Pilgrims Safety

2022-06-22

His Excellency the CEO of Food and Drug Authority (SFDA) Dr. Hisham bin Saad Aljadhey, followed up the supervisory work and the mechanism of clearing food, medicines and medical products at Prince Mohammed bin Abdulaziz Airport in Madinah, in addition to reviewing the awareness programs provided at the SFDA’s pavilion at the airport for pilgrims.

Other News

SFDA’s Product Specific Bioequivalence Guidance

2022-05-24
SFDA’s Product Specific Bioequivalence Guidance
Guide
Has the page content helped you?

British Investors Express Interest in Investing in Food, Drug Market in Saudi Arabia

2022-05-23

His Excellency the CEO of the Saudi Food and Drug Authority (SFDA), Dr. Hisham bin Saad Aljadhey, met during his recent official visit to the United Kingdom, a number of CEOs of British companies, businessmen and representatives of the private sector.

Other News

SFDS Holds Training Workshop for Employees of Bahraini National Health Regulatory Authority

2022-03-24

The Saudi Food and Drug Authority (SFDA) organized a virtual training workshop for employees of the Bahraini National Health Regulatory Authority, entitled "Principles of Good Manufacturing Practice (GMP) and Inspection Procedures", as part of the continuous cooperation between SFDA and the Bahraini National Health Regulatory Authority

Other News

SFDA Signs MoC with Saudi Epilepsy Society

2022-04-13

The Saudi Food and Drug Authority (SFDA) signed on April 12, 2022 a memorandum of cooperation (MoC) with the Saudi Epilepsy Society (SES). The MoC aims to promote and develope the professional, research work of professional specialists and educating the community about epilepsy diseases.

The MOC was signed by His Excellency SFDA’s CEO, Dr. Hisham bin Saad Aljadhey, and SES Chairman Dr. Faisal bin Aboud Al-Otaibi.

Other News

RABEZOLE

Warning Date
    2022-03-17
Manufacture Company

Warning Reason
Correction Actions
Advices to Consumer

SFDA Suspends Registration and Recalls RABEZOLE Product due to its Lack of Bioequivalence with the Reference Product

2022-03-17

The Saudi Food and Drug Authority (SFDA) has issued a decision to recall and suspend the registration of the product (RABEZOLE) for the two registered strengths of 20 mg and 10 mg, (Registration No 95-368-07 and 96-368-07). The products are marketed by Jamjoom Pharmaceuticals. The decision has been taken as the product was found to be not bioequivalent with the reference product.

  • To report sector-related issues

  • Call Centre 19999


Other Warnings

Subscribe to Drugs